Valion Bio, Inc. · NASDAQ:VBIO
Valion Bio — Tivic Health Systems — Investor Presentation (March 2025)
11 slides from Valion Bio's investor presentation, Mar 21, 2025
Slide 1: A diversified therapeutics company
Nasdaq: TIVC A diversified therapeutics company ® ir@tivichealth.com – March 2025 – Jennifer Ernst, CEO, Tivic Health
Slide 2: Tivic Transformation 2024 to 2025
Tivic Transformation 2024 to 2025 Company transformation culminating: from single-product to a diversified therapeutics company - Start of 2024: one product in market, limited pipeline - Today: Growing pipeline of device and drug candidates that regulate autonomic and immune systems Commercial, FDA-
Slide 3: Looking forward, a reinvented company
Looking forward, a reinvented company Complementary modalities create unique therapeutic pipeline Bioelectronic Devices that can reset a hyperactive immune system via neural pathways Biologic Drugs that can stimulate a hypoactive immune system through validated molecular pathways
Slide 4: Complementary modalities create unique therapeutic pipeline
Discovery Proof of Concept Phase I Phase II Phase III Commercial Bioelectronic ClearUP Sinus Pain and Congestion ncVNS Platform development; potential indications in: Neurologic Cardiac Autonomic Biologic (drug) Entolimod™ Acute Radiation Syndrome Immunosenescence* Lymphocyte Exhaustion* Acute Neutr
Slide 5: One commercial product, ClearUP (Trigeminal Nerve Stimulation)
One commercial product, ClearUP (Trigeminal Nerve Stimulation) Clinically proven to clear congestion, relieve sinus pain 16 patents Peer-reviewed papers Est. $9.1B+ US market opportunity based on consumer research+ ~$200 ASP, Gross margin above 65% since September 2024* 2024 Improvements: Product re
Slide 6: Vagus Nerve: High-value Medical Target
Vagus Nerve: High-value Medical Target Current vagus nerve stimulators are primarily surgical implants. Vagus Nerve Clinical Testing conducted by The Institute of Bioelectronic Medicine at Bioelectronic Vagus nerve regulates autonomic nervous system, neurologic, cardiac and immune functions; engages
Slide 7: Vagus Nerve Stimulation Market
Vagus Nerve Stimulation Market Bioelectronic Dominant Approach: Surgically Implanted VNS Rigorous clinical testing FDA regulated and approved Prescribed for medical indications Adoption limited by surgical requirement Approved for Epilepsy, Depression Clinical stage for Rheumatoid Arthritis, Crohn’s
Slide 8: TLR5 Program: In-licensing Agreement
TLR5 Program: In-licensing Agreement Entolimod™ and Entolasta™ are biologic drugs engineered to activate the immune system via agonism of the toll-like receptor 5 (TLR5) Entolimod and Entolasta have undergone numerous animal and human trials; ready for validation, manufacturing and FDA submission Ov
Slide 9: TLR5 Program: Additional Indications
TLR5 Program: Additional Indications In addition to ARS, the Statera licensing agreement comprehends multiple additional indications; flexibility to manage investment. Immunosenescence The gradual age-related decline in the immune system’s function. Entolimod has successfully completed a phase 2 ran
Slide 10: Recap
Recap Company transformation culminating: from single-product to a diversified therapeutics company - Start of 2024: one product in market, limited pipeline - Today: Growing pipeline of device and drug candidates that regulate autonomic and immune systems Commercial, FDA-approved product in market -
Slide 11: A diversified therapeutics company
Nasdaq: TIVC A diversified therapeutics company ® ir@tivichealth.com – March 2025 – Jennifer Ernst, CEO, Tivic Health
Tivic Health Systems — Investor Presentation (March 2025) on 6ix